Not medical advice. I am a software engineer, not a physician. This page documents my own protocol and the research I read while building it. Talk to a qualified clinician before changing your supplementation, diet or any treatment. Lab reference ranges quoted here vary by laboratory and by individual.
Affiliate disclosure: the iHerb links on this page carry a referral code and pay me a commission if you buy. It does not change your price, and I do not link anything I do not use myself.
Body fat is stored in two primary compartments. Subcutaneous fat sits beneath the skin and accounts for approximately 80-90% of total body fat. It is the fat you can pinch with your fingers. While excess subcutaneous fat affects appearance, it is relatively metabolically benign.
Visceral fat (also called intra-abdominal fat) surrounds the internal organs: liver, pancreas, intestines, and kidneys. It accounts for only 10-20% of total fat but is disproportionately harmful. Visceral fat is metabolically active tissue that behaves almost like an endocrine organ, secreting inflammatory cytokines and hormones that disrupt normal metabolic function.
Visceral fat cells (adipocytes) secrete pro-inflammatory cytokines including TNF-alpha, IL-6, and C-reactive protein (CRP). Fontana et al. (2007) measured cytokine production directly from visceral and subcutaneous fat tissue in 30 obese subjects undergoing bariatric surgery and found that visceral fat produced 2-3 times more IL-6 than subcutaneous fat. This chronic low-grade inflammation ("metaflammation") is a key driver of metabolic disease.
Fontana, L., et al. (2007). Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56(4), 1010-1013. PubMed
Visceral fat is directly connected to the liver via the portal vein. Free fatty acids released from visceral fat flood the liver, impairing hepatic insulin sensitivity and increasing hepatic glucose output. This creates a vicious cycle: more visceral fat leads to more insulin resistance, which leads to higher insulin levels, which promotes more fat storage. Despres (2012) documented this "portal hypothesis" extensively, showing that visceral fat accumulation is the strongest predictor of cardiometabolic risk, independent of total body fat.
The INTERHEART study (Yusuf et al., 2004) — a case-control study across 52 countries with 27,098 participants — found that waist-to-hip ratio (a proxy for visceral fat) was a stronger predictor of heart attack risk than BMI. Individuals in the highest quintile of waist-to-hip ratio had a 2.5-fold increased risk of myocardial infarction compared to the lowest quintile.
Yusuf, S., et al. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet, 364(9438), 937-952. PubMed
Computed Tomography (CT) at the L4-L5 vertebral level is the clinical gold standard for quantifying visceral adipose tissue (VAT). MRI provides similar accuracy without radiation. These methods directly visualize and measure the cross-sectional area of visceral fat. However, they are expensive ($200-1000+) and not practical for routine monitoring.
Consumer body composition scales estimate visceral fat using algorithms that combine BIA measurements with age, sex, height, and weight. They typically report a visceral fat "rating" or "level" on a scale of 1-59. While less accurate than CT/MRI, studies by Bosy-Westphal et al. (2006) have shown that BIA-based visceral fat estimates correlate moderately well (r = 0.71-0.82) with CT measurements, making them useful for tracking trends.
The simplest proxy for visceral fat is waist circumference, measured at the navel. Risk thresholds: Men >94 cm (increased risk), >102 cm (substantially increased risk). Women >80 cm (increased risk), >88 cm (substantially increased risk). The WHO recommends waist circumference as a routine clinical measurement alongside BMI.
Most consumer scales (including Xiaomi, Tanita, Omron) use a rating scale for visceral fat. While specific algorithms vary by manufacturer, the general scale is:
| Rating | Level | Health Implication |
|---|---|---|
| 1-9 | Healthy | Normal visceral fat levels. Keep current lifestyle. |
| 10-14 | High | Elevated visceral fat. Increased cardiometabolic risk. Diet and exercise changes recommended. |
| 15-30+ | Very High | Significantly elevated risk. Medical consultation recommended. Aggressive lifestyle intervention needed. |
The good news about visceral fat: it is more metabolically active and therefore responds faster to intervention than subcutaneous fat. When you begin a caloric deficit and exercise program, visceral fat is typically the first fat to be mobilized.
A meta-analysis by Maillard et al. (2018) analyzed 39 studies and found that HIIT reduced visceral fat by 6.3% on average, with greater reductions than moderate-intensity continuous training for the same time investment. The proposed mechanism is increased post-exercise fat oxidation and enhanced catecholamine-driven lipolysis from visceral fat depots.
Maillard, F., et al. (2018). Effect of High-Intensity Interval Training on Total, Abdominal and Visceral Fat Mass: A Meta-Analysis. Sports Med, 48(2), 269-288. PubMed
Resistance training independently reduces visceral fat, even without weight loss, by improving insulin sensitivity and increasing resting metabolic rate. Ismail et al. (2012) conducted a meta-analysis of 35 studies and found that aerobic exercise, resistance training, and their combination all reduced visceral fat, with combination training producing the greatest effect.
Insufficient sleep is directly linked to visceral fat accumulation. Hairston et al. (2010) followed 1,107 adults for 5 years and found that sleeping less than 5 hours per night was associated with a 32% increase in visceral fat accumulation compared to 6-7 hours. Sleeping more than 8 hours also showed increased visceral fat, suggesting a U-shaped relationship.
Chronic stress elevates cortisol, which preferentially promotes visceral fat deposition. Epel et al. (2000) demonstrated that women with greater cortisol reactivity to stress had significantly more visceral fat regardless of BMI. Stress management strategies — meditation, deep breathing, yoga, social connection — are not luxury wellness practices but evidence-based interventions for visceral fat reduction.
A moderate caloric deficit (500 cal/day) preferentially targets visceral fat in the early stages of weight loss. Research suggests that visceral fat loss accounts for a disproportionately large share of total fat lost in the first weeks of a deficit, making even modest weight loss beneficial for metabolic health.
Key insight: You can reduce visceral fat even before you see visible changes in subcutaneous fat. A 5% weight loss (e.g., 4 kg for an 80 kg person) can reduce visceral fat by 10-30%, with significant improvements in insulin sensitivity and inflammatory markers.
A February 2025 study using a large Chinese health screening dataset confirmed that elevated visceral fat area (VFA) is independently associated with metabolic syndrome even in individuals with normal BMI, reinforcing that visceral adiposity, not body weight, is the critical risk driver. Advanced MRI techniques now allow precise quantification of visceral adipose tissue (VAT) using Dixon sequences, water-saturation methods, and T1-weighted imaging. A 2025 RadioGraphics state-of-the-art review documented that multimodality imaging (MRI, CT, echocardiography) can now assess the full spectrum of metabolic syndrome manifestations, including epicardial fat, hepatic steatosis, and coronary artery calcification, enabling earlier detection and more targeted interventions.
Notably, GLP-1 receptor agonists (semaglutide, tirzepatide) have shown preferential visceral fat reduction in 2025 clinical data. The SURMOUNT-1 and SELECT trials demonstrated that tirzepatide reduces visceral fat more aggressively than subcutaneous fat, with the visceral compartment showing disproportionate loss relative to total body weight changes.
PMC (2025). Association between visceral fat area and metabolic syndrome in individuals with normal body weight. BMC Endocrine Disorders. PubMed Central